MRO Magazine

Celprogen Introduces STEMC5007, a Stem Cell Activator / Stimulator That Increases Stem Cell Proliferation and Their Regenerative Potentials for Major Organ Systems

By Business Wire News   



TORRANCE, Calif.

Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed STEMC5007, a synthetic molecule that is capable of stimulating and activating the internal stem cell population. This molecule can be administered by the following methods: intravenous, intra-peritoneal and intramuscular injections, and oral doses. The molecule STEMC5007 activates adult stem cell populations including progenitor stem cells, mesenchymal, skin, human hair follicle stem cells and adipose stem cells.

The present invention relates to increasing the stem cell population within the human organ systems without isolating and expanding the stem cells in a laboratory environment prior to administration of the stem cells back into the human body. The molecule STEMC5007 has been developed and optimized by Celprogen utilizing stem cell tissue culture technology. This technology will have a greater impact for patients that would require stem cell transplants; it works with the existing stem cell population in the individual’s system. This molecule STEMC5007 is an interesting factor to be added to the regenerative medicine therapy and wound healing.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in Torrance, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.

For additional information on the product line contact:

Celprogen Inc.
Jay Sharma, 310-542-8822
info@celprogen.com
www.celprogen.com

Advertisement

Stories continue below

Print this page